Trial Profile
A Double-Blind, Randomized, Placebo-Controlled Multiple Ascending Dose Study to Assess the Safety, Tolerability and Efficacy of KAI-4169 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Etelcalcetide (Primary)
- Indications Secondary hyperparathyroidism
- Focus Therapeutic Use
- Sponsors KAI Pharmaceuticals
- 30 Jul 2020 Results of meta-analysis of four studies ( NCT01785849, NCT01254565, JapicCTI142664 & JapicCTI121978) assessing efficacy and safety of etelcalcetide for the treatment of secondary hyperparathyroidism (SHPT) in patients receiving hemodialysis, published in the Clinical Nephrology.
- 28 Nov 2014 New trial record